PRESS RELEASE REGULATED INFORMATION 6 January 2025, 07:00 am CET / 01:00 am ET Webinar to discuss US commercial roll-out following FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024 alfapump has received PMA Approval[1] and FDA Breakthrough Device Designation Call participants include Dr. Saab,...Read More